id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-285428-fcrunf38	Halstead, Scott B.	COVID-19: The Need for Immunoprevention at Industrial Scale	2020-04-08		.txt	text/plain	684	56	47	Efforts to develop vaccines against Coronavirus disease-19 (COVID-19) are well advanced, based in part on experience with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). 3 Convalescent SARS antibodies given early in illness have been shown to reduce disease severity. 7 Gamma globulin prepared from immune donors or protective monoclonal antibodies offer possibilities of short-term protection for care givers and healthcare workers and, in particular, for those at high risk of severe or fatal COVID-19. To avoid possible enhancement of COVID-19, antibodies might be given to prevent SARS-CoV-2 infections after the removal or inactivation of the IgG Fc terminus. Efforts are well underway by many groups to derive monoclonal antibodies or manufacture gamma globulin from the huge cohort of COVID-19 convalescent immunes. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)	./cache/cord-285428-fcrunf38.txt	./txt/cord-285428-fcrunf38.txt